Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPHNASDAQ:GPCRNASDAQ:LQDANASDAQ:OVAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$25.82-2.3%$24.67$22.64▼$53.96$1.22B0.77488,886 shs402,402 shsGPCRStructure Therapeutics$21.68-2.4%$22.64$13.22▼$52.14$1.24B-1.87855,332 shs669,777 shsLQDALiquidia$14.10-2.4%$15.16$8.26▼$19.41$1.21B0.041.21 million shs1.84 million shsOVASOvaScience$6.61-7.0%$12.74$0.66▼$1.52$236.84M3.11163,131 shs155,687 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-2.34%-0.65%+10.82%-3.15%-36.17%GPCRStructure Therapeutics-2.43%+2.60%-8.98%+2.99%-58.31%LQDALiquidia-2.42%-22.27%-24.40%-2.29%+5.86%OVASOvaScience-4.82%-10.45%+4.71%+746.83%+130.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPHAmphastar Pharmaceuticals4.2346 of 5 stars3.11.00.03.72.84.21.3GPCRStructure Therapeutics2.4276 of 5 stars3.52.00.00.02.81.70.6LQDALiquidia3.7196 of 5 stars4.51.00.00.03.14.20.6OVASOvaScienceN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.25Hold$32.3325.23% UpsideGPCRStructure Therapeutics 3.00Buy$76.50252.86% UpsideLQDALiquidia 3.00Buy$26.8990.70% UpsideOVASOvaScience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OVAS, LQDA, AMPH, and GPCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025LQDALiquidiaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$23.00 ➝ $25.006/11/2025LQDALiquidiaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $23.006/2/2025LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/28/2025LQDALiquidiaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$36.00 ➝ $37.005/28/2025LQDALiquidiaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $23.005/28/2025LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/28/2025LQDALiquidiaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $35.005/27/2025LQDALiquidiaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/19/2025LQDALiquidiaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetMarket Perform ➝ Underperform$13.005/12/2025AMPHAmphastar PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$45.00 ➝ $30.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$730.66M1.67$3.60 per share7.17$13.35 per share1.93GPCRStructure TherapeuticsN/AN/AN/AN/A$9.77 per shareN/ALQDALiquidia$14.14M85.22N/AN/A$0.73 per share19.32OVASOvaScience$290K816.68N/AN/A$1.80 per share3.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$137.54M$2.768.617.852.1921.80%26.44%11.89%8/6/2025 (Estimated)GPCRStructure Therapeutics-$89.62M-$0.87N/AN/AN/AN/A-16.37%-15.68%8/6/2025 (Estimated)LQDALiquidia-$78.50M-$1.58N/AN/AN/A-765.38%-163.21%-67.14%8/6/2025 (Estimated)OVASOvaScience-$50.97MN/A0.00∞N/A-10,128.37%-47.06%-42.39%N/ALatest OVAS, LQDA, AMPH, and GPCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24-$0.27-$0.03-$0.27N/AN/A5/8/2025Q1 2025LQDALiquidia-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million3/19/2025Q4 2024LQDALiquidia-$0.38-$0.46-$0.08-$0.46$4.60 million$2.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ALQDALiquidiaN/AN/AN/AN/AN/AOVASOvaScienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.823.432.61GPCRStructure TherapeuticsN/A27.6327.63LQDALiquidiaN/A6.336.33OVASOvaScienceN/A12.6212.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%GPCRStructure Therapeutics91.78%LQDALiquidia64.54%OVASOvaScience22.52%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.50%GPCRStructure Therapeutics9.43%LQDALiquidia26.50%OVASOvaScience7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,62047.14 million35.05 millionOptionableGPCRStructure Therapeutics13657.34 million51.86 millionOptionableLQDALiquidia5085.49 million59.16 millionOptionableOVASOvaScienceN/A35.83 millionN/ANot OptionableOVAS, LQDA, AMPH, and GPCR HeadlinesRecent News About These CompaniesAssisted Reproductive Technology Market to Surpass USD 40.67 Billion by 2031 | SkyQuest TechnologyAugust 9, 2024 | finance.yahoo.comGlobal Fertility Services Market Report 2024-2032, by Cause of Infertility, Procedure, Service, End-User and RegionMay 21, 2024 | uk.finance.yahoo.comIn Vitro Fertilization Market Will Increase USD 40.6 Billion By 2032 With Around 7.8% CAGRApril 2, 2024 | pharmiweb.comInfertility Services Market Set for Remarkable Expansion, Worth USD 3.8 Billion by 2033 | Market.usMarch 13, 2024 | pharmiweb.comGeneral Catalyst Group V LP's Net WorthFebruary 11, 2024 | benzinga.comGlobal In Vitro Fertilization Market Size To Worth USD 39.12 Billion By 2032 | CAGR of 5.5%December 7, 2023 | finance.yahoo.comOvascience (OVAS) Stock Drops After Pricing Public OfferingNovember 4, 2023 | thestreet.comGlobal Retail Automation Market Size 2023-2027 | Drivers, Product Types, Applications, Growth Analysis and ForecastJune 30, 2023 | finance.yahoo.comTMRW Life Sciences Names Louis Villalba Chief Executive OfficerJune 27, 2023 | markets.businessinsider.comIVF Devices and Consumables Market Research Report 2023 Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2030June 22, 2023 | marketwatch.comOcuTerra Appoints Bill Steinkrauss as Chief Financial OfficerJune 1, 2023 | finance.yahoo.comIVF Market Business Approaches by 2030May 15, 2023 | marketwatch.comIVF Devices Market is Predicted to Reach US$ 6367 million by 2027 ... - StreetBuzzMay 14, 2023 | news.google.comSemen Analysis System Market SWOT analysis of key factors to ... - StreetBuzzMay 13, 2023 | news.google.comDonor Egg IVF Treatment Market Statistics, Share Price, Growth ... - Digital JournalMay 12, 2023 | news.google.comIVF Instruments Market Insights, Rising Trends and Global Demand ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comAssisted Reproductive Technologies (ART) Market Size Growth and ... - Cottonwood Holladay JournalMay 10, 2023 | news.google.comAssisted Reproductive Technology Market Expected to Reach USD 54.75 Billion by 2028 at a 9.7% CAGR - openPRMay 10, 2023 | news.google.comGlobal Assisted Reproductive Technology Market Global Segments ... - Cottonwood Holladay JournalMay 9, 2023 | news.google.comIn Vitro Fertilization Market is Expected to Reach USD 36.51 Billion ... - EIN NewsMay 9, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings3 Penny Stocks Analysts Believe Are Headed HigherBy Chris Markoch | June 4, 2025View 3 Penny Stocks Analysts Believe Are Headed HigherOVAS, LQDA, AMPH, and GPCR Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$25.82 -0.62 (-2.34%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$25.83 +0.01 (+0.04%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Structure Therapeutics NASDAQ:GPCR$21.68 -0.54 (-2.43%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$21.70 +0.02 (+0.07%) As of 06/13/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Liquidia NASDAQ:LQDA$14.10 -0.35 (-2.42%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$14.26 +0.16 (+1.13%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.OvaScience NASDAQ:OVASMillendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
